Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2011

01-08-2011 | Erratum

Erratum to: Postmenopausal estrogen monotherapy–associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism

Author: The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Excerpt

Unfortunately affiliations of all authors/consortium members and information on the writing group have been missed out in the original publication; they are given below. …
Metadata
Title
Erratum to: Postmenopausal estrogen monotherapy–associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism
Author
The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Publication date
01-08-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0880-5

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue

Preclinical study

FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer

Letter to the Editor

Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study

Letter to the Editor

XPC gene polymorphisms and breast cancer susceptibility: appraisal of a recent meta-analysis

Brief Report

Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature

Clinical trial

Clinical application of shear wave elastography (SWE) in the diagnosis of benign and malignant breast diseases

Epidemiology

Alcohol, tobacco, and mammographic density: a population-based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits